Key terms
About ACAD
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACAD news
Today
5:05am ET
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
Today
1:27am ET
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
Yesterday
8:30am ET
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Yesterday
6:57am ET
Positive Buy Rating for ACADIA Pharmaceuticals Amid Solid Market Presence and Underestimated Long-Term Opportunities
Yesterday
6:48am ET
RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)
Yesterday
6:46am ET
Maintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth Prospects
Yesterday
6:10am ET
Acadia Pharmaceuticals price target lowered to $28 from $31 at Baird
Yesterday
5:56am ET
Acadia Pharmaceuticals price target lowered to $30 from $30.19 at Citi
Yesterday
12:45am ET
ACADIA Pharmaceuticals: Strong Sales and Promising Pipeline Justify Buy Rating
May 08
4:17pm ET
Acadia Pharmaceuticals sees FY24 NUPLAZID net sales $560M-$590M
May 08
4:17pm ET
Acadia Pharmaceuticals reports Q1 EPS 10c, consensus 5c
May 08
3:34pm ET
Acadia options imply 15.2% move in share price post-earnings
May 06
7:50am ET
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
Apr 22
9:22am ET
Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
Apr 17
4:07pm ET
Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
Apr 09
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Apr 08
10:40pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Apr 01
8:46am ET
Largest borrow rate increases among liquid names
Mar 25
8:48am ET
Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
Mar 15
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Mar 14
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
8:46am ET
Acadia Pharmaceuticals price target lowered to $30 from $40 at Morgan Stanley
Mar 12
9:51am ET
Oracle, Dollar General upgraded: Wall Street’s top analyst calls
Mar 12
9:23am ET
Acadia Pharmaceuticals price target lowered to $32 from $36 at Needham
Mar 12
9:18am ET
Acadia Pharmaceuticals price target lowered to $30 from $35 at RBC Capital
Mar 12
8:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)
Mar 12
7:43am ET
Acadia Pharmaceuticals price target lowered to $19 from $25 at Oppenheimer
Mar 12
6:46am ET
Acadia Pharmaceuticals price target lowered to $31 from $40 at Baird
Mar 12
6:35am ET
Acadia Pharmaceuticals price target lowered to $30 from $33 at BofA
Mar 12
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)
Mar 12
6:22am ET
Acadia Pharmaceuticals price target lowered to $33 from $40 at Canaccord
Mar 27
10:37am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation
Mar 19
8:50am ET
Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)
Mar 13
3:22pm ET
Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)
Mar 13
7:04am ET
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Mar 12
7:02am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
ACAD Financials
Key terms
Ad Feedback
ACAD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACAD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
